Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al
- PMID: 22388160
- DOI: 10.1097/JCP.0b013e318248daaa
Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al
Comment on
-
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.J Clin Psychopharmacol. 2011 Jun;31(3):349-55. doi: 10.1097/JCP.0b013e318218dcd5. J Clin Psychopharmacol. 2011. PMID: 21508856 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
